Emergent BioSolutions Acquires Advanced Recombinant Protective Antigen Anthrax Vaccine Candidate And Technology
May 15th 2008Drug InformationBio-terrorism
Emergent BioSolutions Inc. (NYSE: EBS) announced that it has completed the acquisition of all assets and rights related to a recombinant protective antigen (rPA) anthrax vaccine product candidate and related technology from VaxGen, Inc. Recent improvements to the rPA vaccine, specifically related to stability, suggests that it is well positioned to be a leading candidate for an award under a request for proposal (RFP) recently issued by the U.S. Department of Health and Human Services (HHS).
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
